

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 197 558 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

17.04.2002 Bulletin 2002/16

(51) Int Cl.7: **C12N 15/82, C12N 9/10,
C12N 15/11**

(21) Application number: **01122628.9**

(22) Date of filing: **27.09.2001**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

Designated Extension States:

AL LT LV MK RO SI

• **Kusano, Tomonobu**

Nara City, Nara Pref. (JP)

• **Koizumi, Nozomu**

Ikoma City, Nara Pref. (JP)

(30) Priority: **06.10.2000 JP 2000307149**

(71) Applicant: **Nara Institute of Science and
Technology**

Ikoma City, Nara Pref. (JP)

(74) Representative:

Wibbelmann, Jobst, Dr., Dipl.-Chem.

Wuesthoff & Wuesthoff,

Patent- und Rechtsanwälte,

Schweigerstrasse 2

81541 München (DE)

(72) Inventors:

• **Sano, Hiroshi**

Ikoma City, Nara Pref. (JP)

(54) **Theobromine synthase polypeptide of coffee plant and the gene encoding said polypeptide**

(57) According to the present invention, the polypeptide of theobromine synthase derived from *coffee arabica* and the gene encoding said polypeptide are provided. As theobromine synthase participates in bio-

synthesis of caffeine, caffeineless coffee would be obtained by preparing a transformed plant, wherein expression of gene encoding said enzyme is inhibited.

BEST AVAILABLE COPY

EP 1 197 558 A2

Description**BACKGROUND OF THE INVENTION****1. Field of the invention**

[0001] This invention relates to theobromine synthase polypeptide and the gene encoding said enzyme.

2. Prior art

[0002] Coffee is a drink consumed all over the world with favorite and its utility is markedly large. On the other hand, it is known that excessive ingestion of caffeine, which is contained in coffee, causes harmful effects. Caffeine is one of xanthine derivatives and theophylline and theobromine are also the members of the xanthine derivatives. These xanthine derivatives are known to inhibit phosphodiesterase, thereby the amount of cAMP is increased. As the result, xanthine derivatives exhibit excitatory effect on the central nerves system and enhance function of the circulatory system. When they are ingested at a suitable amount, such effects of xanthine derivatives are useful for spiritual elevation. However, when the amount of digestion is excessive, they would cause harmful effects as mentioned above. Therefore, there has been a strong demand on production of a caffeine-less coffee all over the world.

[0003] To obtain caffeine-less coffee, attempts to obtain a gene involved in biosynthesis of xanthine derivatives have been performed, in the purpose to achieve artificial control of biosynthesis of caffeine. In Fig. 1 (cited from Advances in Botanical Research, Vol. 30, Academic Press (1999) p149), the pathway working for caffeine biosynthesis in coffee plants is shown. In Fig. 1, the arrow with solid line indicates the main pathway of caffeine synthesis and the arrow with dotted line indicates the minor pathway of caffeine synthesis, respectively. As shown in the second line of Fig. 1, the pathway operating for biosynthesis of caffeine from xanthosine via 7-methylxanthine and theobromine has been known, which is the main pathway for biosynthesis of caffeine biosynthesis in coffee plants. The latter half of the main biosynthesis pathway of caffeine is composed of three steps of N-methylation reactions. These N-methylation reactions have been known to be dependent on S-adenosylmethionine. There also exists a pathway (third line in Fig. 1) in which caffeine is biosynthesized from 7-methylxanthine via para-xanthine, but it is known that contribution of this pathway is not significant. With regard to the first methylation reaction to synthesize 7-methylxanthine, a gene encoding an enzyme responsible for said reaction has been obtained and it has been already reported (International Laid-Open Publication No. WO 97/35960). However, genes involved in the second step methylation reaction and the third step methylation reaction have not been known yet. For effective and accurate manipulation of caffeine biosynthesis, more knowledge on genes that encode enzymes involved in caffeine biosynthesis should be obtained.

SUMMARY OF THE INVENTION

[0004] The first aspect of this invention is a polypeptide consisting of an amino acid sequence defined by amino acid numbers from 1 to 378 shown in SEQ ID NO: 1 in a Sequence List. A polypeptide consisting of an amino acid sequence exhibiting at least 90% of homology with SEQ ID NO: 1 is also within the scope of this invention, so far as the polypeptide has the activity to biosynthesize theobromine using 7-methylxanthine as the substrate. Such sequence may be obtained by making deletions, insertions, substitutions or any combinations thereof in the amino acid sequence of SEQ ID NO: 1.

[0005] The second aspect of this invention is a gene consisting of a base sequence defined by base numbers from 1 to 1298 shown in SEQ ID NO: 2 in a Sequence List. A gene that hybridizes with SEQ ID NO: 2 under a stringent condition and a gene consisting of a base sequence exhibiting at least 90% of homology with SEQ ID NO: 2 is also within the scope of this invention, so far as the gene encodes a polypeptide having the activity to biosynthesize theobromine using 7-methylxanthine as the substrate. Such sequence may be obtained by making deletions, insertions, substitutions or any combinations thereof in the base sequence of SEQ ID NO: 2.

[0006] The third aspect of this invention is a transformed plant wherein expression of said gene is inhibited in the plant to decrease biosynthesis of theobromine and a seed obtained from the transformed plant. Preferably, the plant to be transformed is selected from the group consisting of *Coffea arabica*, *Coffea canephora*, *Coffea liberica* and *Coffea dewevrei*.

[0007] The fourth aspect of this invention is a transformed plant wherein said gene is introduced in the plant to increase biosynthesis of theobromine and a seed obtained from the transformed plant. Preferably, the plant to be transformed is selected from the group consisting of *Coffea arabica*, *Coffea canephora*, *Coffea liberica* and *Coffea dewevrei*.

BRIEF DESCRIPTION OF THE DRAWINGS

[0008] The present invention will be further explained in detail hereafter with reference to the accompanying drawings, in which:

Fig. 1 is a drawing showing the pathway of caffeine biosynthesis ;

Fig. 2 is a drawing showing base sequences of cDNAs obtained from MTL1, MTL2, MTL3 and MXMT1;

Fig. 3 is a drawing showing alignment of amino acid sequences obtained from MXMT1, MTL2 and MTL3 ;

Fig. 4 is a photograph showing the results of SDS-PAGE analyses performed on fusion proteins obtained from MTL2, MTL3 and MXMT1 ;

Fig. 5 is a photograph showing the results of TLC to analyze enzymatic activities of the fusion proteins obtained from MTL2, MTL3 and MXMT1 ; and

Fig. 6 is a chart showing the results of HPLC performed to identify reaction products in the enzymatic reaction mixture of the fusion protein obtained from MXMT1 identified by HPLC.

DETAILED DESCRIPTION OF THE INVENTION

[0009] The present inventors remarked an enzyme participating to the second methylation step reaction and responsible for biosynthesis of theobromine, and they have obtained the gene encoding the enzyme. The enzyme is an enzyme operating to catalyze biosynthesis of theobromine from 7-methylxanthine. Therefore, when expression of the gene encoding said enzyme is inhibited, it would result in decrease of theobromine biosynthesis. In the pathway of caffeine biosynthesis, caffeine is synthesized through N-methylation of theobromine. Then when biosynthesis of theobromine is inhibited, biosynthesis of caffeine would be inhibited as well. As described above, theobromine and caffeine exhibit similar pharmacological effect as xanthine derivatives. Therefore, isolation of a gene encoding an enzyme, which enables concurrent manipulation of theobromine biosynthesis and caffeine biosyntheses, has a great significance. That is, if a gene encoding an enzyme responsible for the final step of caffeine biosynthesis, i.e. the third methylation step, is isolated, then expression of the gene can be inhibited. As a result, biosynthesis of caffeine would be reduced, but biosynthesis of theobromine would not be reduced. Moreover, accumulation of theobromine is expected to occur, as the metabolism of theobromine is inhibited. Thus, considering that pharmacological effect of theobromine is similar to that of caffeine, the effect of the present invention, which relates to isolation of a gene encoding theobromine synthase, can be estimated to be significant.

[0010] The present invention relates to theobromine synthase gene derived from *Coffea arabica*, consisting of a base sequence defined by the base numbers 1 to 1298 shown in SEQ.ID. NO:2 in a Sequence List. As described above, in coffee plants, theobromine synthase catalyzes methylation reaction at biosynthesis of theobromine using 7-methylxanthine as the substrate. The gene defined by the base sequence described in SEQ.ID. NO:2 in a Sequence List is a gene encoding theobromine synthase having such characteristic.

[0011] According to technique of gene recombination, artificial modification can be achieved at a specific site of basic DNA, without alteration or with improvement of basic characteristic of said DNA. Concerning a gene having native sequence provided according to this invention or modified sequence different from said native sequence, it is also possible to perform artificial modification such as insertion, deletion or substitution to obtain gene of equivalent or improved characteristic compared with said native gene. Moreover, a gene with such mutation is also included in the range of this invention. That is, the gene, consisting of a base sequence hybridizes with said base sequence shown in SEQ ID NO: 2 in the sequence list under stringent condition, means a gene in which 10 or less, preferably 7 or less, and more preferably 3 or less bases of the sequence is deleted, substituted or added to the base sequence shown in SEQ ID NO: 2 in a Sequence List. Moreover, such gene exhibits homology 90% or more, preferably 95% or more and still preferably 99% or more with the base sequence shown in the SEQ ID NO: 2 in a Sequence List under stringent condition. Such gene hybridizes with the base sequence shown in the SEQ ID NO: 2 in a Sequence List under stringent condition. Such gene is also within the range of this invention so far as it encodes a polypeptide having the characteristic as theobromine synthase, that catalyzes biosynthesis of theobromine using 7-methylxanthine as the substrate.

[0012] Furthermore, this invention relates to polypeptide of theobromine synthase derived *Coffea arabica*, consisting of an amino acid sequence defined by the amino acid numbers from 1 to 378 shown in SEQ ID NO: 1 in a Sequence List. The polypeptide consisting of an amino acid sequence in which a part of said polypeptide defined by amino acid sequence shown in SEQ ID NO: 1 is deleted, substituted or added with another amino acid sequence means a polypeptide in which 10 or less, preferably 7 or less, and more preferably 3 or less amino acids of the sequence is deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 1 in a Sequence List. Moreover, such polypeptide exhibits homology 90% or more, preferably 95% or more and still preferably 99% or more with the amino acid sequence shown in SEQ ID NO: 1 in a Sequence List. Such polypeptide is also within the range of this invention so far as it exhibits characteristic as theobromine synthase, that catalyzes biosynthesis of theobromine using 7-methylxanthine

as the substrate. Incidentally, the polypeptides shown in SEQ.ID. NO:3, SEQ.ID. NO:5 and SEQ.ID. NO:7 in a Sequence List can be obtained from coffee arabica (*Coffea arabica*), and the polypeptides have higher than 80% of homology compared with the amino acid sequence of SEQ.ID. NO:1 in a Sequence List. These three polypeptides did not exhibit activity as theobromine synthase, despite of high homology to SEQ.ID. NO:1 in a Sequence List.

[0013] A transformed plant, in which expression of theobromine synthetase gene described in SEQ.ID. NO:2 in a Sequence List is inhibited to decrease biosynthesis of theobromine, is also within the scope of the present invention. The theobromine synthase gene of the present invention is, as mentioned above, a gene encoding an enzyme involved in biosynthesis of theobromine in coffee arabica. Thus, by inhibiting expression of the gene according to the present invention, biosynthesis of theobromine is assumed to decrease in a plant, whereby it enables decrease of theobromine content and caffeine content in the plant. As a plant of the target in which expression of theobromine synthase gene of the present invention is inhibited, coffee plants such as *Coffea arabica*, *Coffea canephora*, *Coffea liberica* and *Coffea dewevrei* and the like can be exemplified.

[0014] In these plants, by inhibiting expression of the gene of the present invention, biosyntheses of theobromine and caffeine would be reduced. As a means for inhibiting expression of the gene of the present invention, a method utilizing an antisense gene (antisense gene method) can be adopted. The antisense gene means a gene that expresses a base sequence complementary to mRNA, a transcription product of DNA constituting a certain gene. The transcription product of the antisense gene is complementary to an inherent mRNA, then the antisense gene can inhibit gene expression at the stage of translation. By utilizing this technique, expression of theobromine synthase gene can be inhibited.

[0015] In addition, other methods that can inhibit expression of a gene have been known. By destruction of a targeted gene, expression of the gene can be inhibited. Moreover, in a plant, technique of co-suppression (transwitch technique) has been known. According to the technique, expression of the targeted gene can be inhibited by phenomenon of gene interference, even when sense gene is introduced and over-expressed. Moreover, it has been reported in recent years that Doublestranded RNA interference (RNAi) method using a double stranded RNA is effective to inhibit expression of a gene (Chiou-Fen Chuang et al. PNAS (2000) vol. 97, 4985-4990). It has been demonstrated that a double strand RNA can inhibit expression of a gene in a sequence specific manner, according to the research mainly utilizing nematodes (*C.elegans*) or fruit fly. In the RNAi method, such double strand RNA is utilized and it has been recently demonstrated that the method is effective for not only nematodes or fruit fly but also for plants such as *Arabidopsis thaliana* Heynh. The mechanism involved in inhibition of gene expression by the RNAi method is not known yet. However, this method would enable inhibition of expression of a gene, with higher efficiency compared with the above-mentioned antisense method.

[0016] By the way, purine alkaloids such as caffeine and theobromine, can exhibit effect to avoid insects and the effect is considered to be the existence value of purine alkaloids in a plant. Thus, the gene of the present invention can be introduced in a plant and biosynthesis of theobromine can be increased in the plant, whereby the plant body would exhibit insect-avoiding activity. As described above, the enzyme of the present invention is responsible for biosynthesis of theobromine using 7-methylxanthine as the substrate. Therefore, it is assumed that, when the above-mentioned gene encoding the 7-methylxanthine synthase (International Laid-Open Publication WO 97/35960) and the gene of the present invention are introduced into a plant concurrently, the effect would be particularly significant. When the activity of 7-methylxanthine synthase is enhanced, the amount of substrate available for the enzyme according to the present invention would be increased. As a result, accumulation of theobromine, which is the objective product, is expected to occur.

[0017] As a method to produce a transformant, a method generally well known in this art can be adopted. A vector available for the present invention may include plasmid vectors, for example pBI121 can be exemplified, but the scope the vector is not to be limited to them. Such vector can be introduced into, for example, *Agrobacterium*. Then the bacteria can be utilized for infection of callus or plantlets, resulting in production of transformed plants. Furthermore, it is possible to obtain seeds derived from such transformed plants. In Japanese Laid-Open Patent Application No. 2000-245485, the present inventors have reported a method comprising infection of an embryogenic callus of a coffee plant by *Agrobacterium tumefaciens* EHA101 and the method enables transformation of coffee plants with high efficacy. The method for transformation described in Japanese Laid-Open Patent Application No. 2000-245485 is assumed to be particularly useful.

EXAMPLES

(Amplification by PCR)

[0018] A pair of degenerate oligonucleotide (Forward primer, GGITGYDSIDSIGGICCAAYAC; Reverse primer, AR-IYKIYYRTRRAAISWICIGG) was synthesized, based on the region conserved among TCS1 (Kato et al., 2000, GenBank accession no. AB031280) and two proteins (Z99708 and AC008153), with their functions unknown, of *Arabidopsis*

thaliana. These oligonucleotides correspond to amino acid sequences of GC(A/S)(A/S)GPNT and PGSF(H/Y)(G/K)(R/N)LF, respectively. In a 25 µl of reaction mixture containing *Coffea arabica* cDNA and the above-mentioned primer pair, PCR was performed under the conditions described below. That is, after reaction at 94°C for one minute, 30 cycles of denaturation at 94°C for 30 seconds, annealing at 52°C for 30 seconds and extension at 72°C for one minutes was performed, which was followed by a final extension at 72°C for 7 minutes, whereby the PCR reaction was completed. The amplified cDNA fragment of about 270 base pairs was used for screening of cDNA library.

(cDNA library construction and screening)

[0019] Total RNA was extracted from young leaves of coffee (*Coffea arabica*) and it was purified to mRNA by oligo-dT column (Pharmacia). cDNA was synthesized from mRNA using ZAPII cDNA synthesis kit (Stratagene), it was introduced into λZAPII vector to prepare phage library. Then cDNA library was screened using the above-mentioned amplified fragment as a probe. Thirty-five of resulting positive plaques were selected randomly and converted to plasmids, then physical mapping and partial sequencing were performed. As a result, they were clarified into 4 groups of independent clones.

[0020] Clones #1, #6, #35 and #45 were representatives of each group having the longest lengths close to full length cDNAs, and base sequences of the clones were determined. Moreover, the deduced amino acid sequences encoded by the open reading frame regions of the base sequences were determined. The base sequences determined by sequencing were shown in Fig. 2. The base sequence of cDNA obtained on the clone #45 was shown in SEQ.ID. NO: 2 in a Sequence List and in Fig. 2D. The region corresponding to open reading frame of said gene ranged from base numbers 32 to 1168, and the deduced amino acid sequence encoded by said region was shown in SEQ.ID. NO:1 in a Sequence List. Moreover, the base sequence of cDNA obtained on the clone #1 was shown in SEQ.ID. NO:4 in a Sequence List and in Fig. 2A. The region corresponding to open reading frame of said gene ranged from base numbers 14 to 1171, and the deduced amino acid sequence encoded by said region was shown in SEQ.ID. NO:3 in a Sequence List. Furthermore, the base sequence of cDNA obtained on the clone #6 was shown in SEQ.ID. NO:6 in a Sequence List and in Fig. 2B. The region corresponding to open reading frame of said gene ranged from base numbers 44 to 1201, and the deduced amino acid sequence encoded by said region was shown in SEQ.ID. NO:5 in a Sequence List. Moreover, the base sequence of cDNA obtained on the clone #35 was shown in SEQ.ID. NO:8 in a Sequence List and in Fig. 2C. The region corresponding to open reading frame of said gene ranged from base numbers 45 to 1163, and the deduced amino acid sequence encoded by said region was shown in SEQ.ID. NO:7 in a Sequence List. In the following, the gene corresponds the clone #45 was designated to MXMT1, the clone #1 was designated to MTL1, the clone # 6 was designated to MTL2, and the clone #35 was designated to MTL3, respectively.

[0021] The alignment compared among amino acid sequences encoded by MXMT1, MTL1, MTL2 and MTL3 was shown in Fig. 3. As a result, it was shown that these four sequences exhibit extremely high homology. To confirm the functions charge by these polypeptides, genes corresponding to each clone were expressed in *E. coli* to confirm their enzymatic activities.

(Expression of GST fused protein)

[0022] The open reading frame regions of MTL1 (Clone #1), MTL2 (Clone #6), MTL3 (Clone #35) and MXMT1 (Clone #45) were amplified by PCR (polymerase chain reaction). Then, they were optionally cloned into pGEX 4T-2 vector (Pharmacia) and *E. coli* (JM109) cells were transformed with the resulting plasmids. The obtained *E. coli* cells were cultured in LB liquid medium containing ampicillin. When OD600 of the culture reached to 0.5, IPTG (isopropyl thio-β-D-galactoside) was added to it and the final concentration of IPTG was made to 1 mM, then the mixture was further cultured at 16°C for 6 hours. *E. coli* was disrupted by a sonicator and the protein of the purpose was purified by glutathione Sepharose 4B as a GST (glutathione S-transferase) fusion protein. Concentration of the protein was measured by the Bradford method. Each of the GST fusion protein (500 ng) was separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), then it was stained by CBB (coomassie Brilliant Blue) to confirm purification. The purities of the resulting GST fusion proteins were analyzed by SDS-PAGE and the results were shown in Fig. 4. In Fig. 4, lane 1 shows the result of MTL2 fusion protein, lane 2 shows the result of MTL3 fusion protein, lane 3 shows the result of MXMT1 fusion protein, respectively. As a result, the resulting three fusion proteins were shown to be approximately pure.

(Measurement of enzymatic activities by thin layer chromatography)

[0023] Measurement of enzymatic activity was performed using thin layer chromatography (TLC), based on the method of Kato et al. (*Plant Physiol.*, 1996, 98, 629-636). In concrete, the reaction mixture of 100 µl, containing 100 mM Tris-HCl (pH 7.5), 200 µM substrate (xanthine, 7-methylxanthine, theobromine, paraxanthine, theophylline), 4 µM ¹⁴C-

labeled S-adenosylmethionine, 200 μ M $MgCl_2$, 200 ng GST fusion protein, was incubated at 27°C for 2 hours. After the reaction, the resulting mixture was extracted with 1 ml of chloroform, the chloroform layer was recovered, then chloroform was evaporated by speed back concentrator. The residue was dissolved in 5 μ l of 50% methanol solution, then the solution was developed by TLC (solvent for development was water:acetic acid:n-butanol= 2:1:4, v/v/v). After the development, signal of radio activity was detected by image analyzer (Fuji BAS 2000). The result of enzymatic activity, which was measured on the fusion proteins derived from MTL2, MTL3 and MXMT1 using xanthine (X), 7-methylxanthine (7-Mx), theobromine (Tb), paraxanthine (Px) and theophylline (Tp) as the substrate, was shown in Fig. 5. From Fig. 5, it was revealed that the fusion protein derived from MXMT1 exhibited potent activity to synthesize theobromine, using 7-methylxanthine as the substrate. The fusion protein derived from MXMT1 also exhibited activity to synthesize caffeine, using paraxanthine as the substrate, but its relative activity was 15% of the above-mentioned activity. On the other hand, the fusion proteins derived from MTL2 and MTL3 did not exhibit activity as a methyl transferase, using the above-mentioned compounds as the substrate.

(Enzymatic activity measurement and identification of the product by HPLC)

[0024] Using high performance liquid chromatography (HPLC), enzymatic activity of the MXMT1 fusion protein was measured and reaction product obtained from the enzymatic reaction was identified. The reaction mixture of 100 μ l, containing 100 mM Tris-HCl (pH 7.5), 200 μ M of substrate (7-methylxanthine, paraxanthine, theobromine), 50 μ M of S-adenosylmethionine, 200 μ M of $MgCl_2$, 200 ng of GST fusion protein, was incubated at 27°C for 2 hours. After incubation, the mixture was extracted with 1 ml of chloroform, the chloroform layer was recovered, then chloroform was evaporated by a speed back concentrator. The residue was dissolved in 50 μ l of 12% acetonitrile. Then the solution was fractionated by HPLC (Shodex Rspak DS-613 column) provided with UV detection system. As the solution for development, 12% acetonitrile was used and the signal was detected for absorbance of 254 nm.

[0025] The result was shown in Fig. 6. The MXMT1 fusion protein was reacted with S-adenosylmethionine and 7-methylxanthine, which is the substrate and the reaction product was analyzed by HPLC. The chart exhibiting the result was shown in Fig. 6A. Moreover, theobromine was analyzed for a standard compound using HPLC and the chart exhibiting the result was shown in Fig. 6B. For preparation of negative standard, the MXMT1 fusion protein, S-adenosylmethionine and 7-methylxanthine was mixed and the reaction was immediately stopped and the chart exhibiting the result was shown in Fig. 6C. For standard products, 7-methylxanthine, theobromine, paraxanthine and caffeine were analyzed by HPLC, and the chart exhibiting the result was shown in Fig. 6D. Furthermore, S-adenosylmethionine and 7-methylxanthine was reacted with MXMT1 fusion protein and then theobromine was added to the reaction mixture. The chart exhibiting the result was shown in Fig. 6E. The peak position of the reaction product detected in Fig. 6A coincided with the position of theobromine, which was analyzed as the standard compound. In addition, when theobromine was added to the enzymatic reaction mixture, only one peak was observed. Therefore, it was shown that theobromine was formed by enzymatic reaction of the MXMT1 fusion protein, using 7-methylxanthine as the substrate.

[0026] According to the present invention, the polypeptide of theobromine synthase derived from *coffea arabica* and the gene encoding said polypeptide were provided. As theobromine synthase participates in biosynthesis of caffeine, caffeineless coffee would be obtained by preparing a transformed plant, wherein expression of gene encoding said enzyme was inhibited.

Sequence Listing

<110> President of Nara Institute Science and Technology

<120> Theobromine synthase polypeptide of coffee plant and the gene encoding said polypeptide

<160> 8

<210> 1

<211> 378

<212> Amino acid

<213> Coffea arabica

<400> 1

```

MELQEVLMHN EGEGETSYAK NASYNLALAK VKPFLEQCIR ELLRANLPNI NKCIKVADLG   60
CASGPNTLLT VRDIVQSIDK VGQEEKNELE RPTIQIFLND LFQNDFNSVF KLLPSFYRKL  120
EKENGKRKIGS CLISAMPGSF YGRLFPEESM HFLHSCYSVH WLSQVPSGLV IELGIGANKG  180
SIYSSKGCPR PVQKAYLDQF TKDFTTFLRI HSKELFSRGR MLLTCICKVD EFDEFNPLDL  240
LDMAINDLIV EGGLEEEKLD SFNIPFFTPS AEEVKCIVEE EGSCEILYLE TFKAHYDAAF  300
SIDDDYPVRS HEQIKAHEYVA SLIRSVYEPI LASHFGEAIM PDLFHLRAKH AAKVLHMGKG  360
CYNLNLIISLA KKPEKSDV                                     378

```

<210> 2

<211> 1298

<212> Nucleic acid

<213> Coffea arabica

<400> 2

```

AGCAGTCGCA ATTCGATTGT CCTGCATATG AATGGAGCTC CAAGAAGTCC TGCATATGAA   60
TGAAGGTGAA GGCGATACAA GCTACGCCAA GAATGCATCC TACAATCTGG CTCTTGCCAA  120
CGTCAAACCT TACCTTCAAC AATGCATACG ACAATTCTTG CGGGCCAACT TCCCCAACAT  180
CAACAAGTGC ATTAAAGTTG CGGATTTGGG ATGCGCTTCT GGACCAAACA CACTTTTAAC  240
AGTGCGGGAC ATTGTGCAAA GTATTGACAA AGTTGCCAG GAAGAGAAGA ATGAATTAGA  300
ACGTCCCACC ATTCAGATTT TTCTGAATGA TCTTTTCCAA AATGATTTC AATCGGTTTT  360
CAAGTTGCTG CCAAGCTTCT ACCGCAAAC TCGAGAAAGAA AATGGACGCA AGATAGGATC  420
GTGCCTAATA AGCGCAATGC CTGGCTCTTT CTACGGCAGA CTCTTCCCCG AGGAGTCCAT  480
GCATTTTTTG CACTCTTGTT ACAGTGTTCA TTGGTTATCT CAGGTTCCCA GCGGTTTGGT  540

```

EP 1 197.558 A2

5 GATTGAATTG GGGATTGGTG CAAACAAAGG GAGTATTTAC TCTTCCAAAG GATGTCGTCC 600
 GCCCGTCCAG AAGGCATATT TGGATCAATT TACGAAAGAT TTTACCACAT TTCTAAGGAT 660
 TCATTGAAA GAGTTGTTTT CACGTGGCCG AATGCTCCTT ACCTGCATTT GTAAAGTAGA 720
 TGAATTCGAC GAACCGAATC CCCTAGACTT ACTTGACATG GCAATAAACG ACTTGATTGT 780
 10 TGAGGGACTT CTGGAGGAAG AAAAATTGGA TAGTTTCAAT ATTCCATTCT TTACACCTTC 840
 AGCAGAAGAA GTAAAGTGCA TAGTTGAGGA GGAAGGTTCT TGCGAAATTT TATATCTGGA 900
 GACTTTTAAG GCCCATTATG ATGCTGCCTT CTCTATTGAT GATGATTACC CAGTAAGATC 960
 CCATGAACAA ATTAAAGCAG AGTATGTGGC ATCATTAAAT AGATCAGTTT ACGAACCCAT 1020
 15 CCTCGCAAGT CATTTTGGAG AAGCTATTAT GCCTGACTTA TTCCACAGGC TTGCGAAGCA 1080
 TGCAGCAAAG GTTCTCCACA TGGGCAAAGG CTGCTATAAT AATCTTATCA TTTCTCTCGC 1140
 CAAAAAGCCA GAGAAGTCAG ACGTGTAATA GTTTGTTTTT AGTTGGTTTT TGTGCCGTTG 1200
 20 GGGGTCTTTC GGGTATTGTC GTTTTGTATT CGTAATAAAA GTGATGTGCA AGAATAAGAT 1260
 ATTTAGTACA ATATTTTCAT AAAAAAAAAA AAAAAAAA 1298
 25 <210> 3
 <211> 385
 <212> Amino acid
 30 <213> Coffea arabica
 <400> 3
 MELQEVLMHN GGEGEASYAK NSSFNQLVLA KVKPVLEQCV RELLRANLPN INKCIKVADL 60
 35 GCASGPNTLL TVWDTVQSID KVKQEMKNEL ERPTIQVFLT DLFQNDFNSV FMLLPSFYRK 120
 LEKENGKRKIG SCLIAAMPGS FHGRLFPEES MHFLHSSYSL QFLSQVPSGL VTELGITANK 180
 RSIYSSKASP PPVQKAYLDQ FTKDFTTFLR MRSEELLSRG RMLLTICKG DECDGPNTMD 240
 40 LLEMAINDLV AEGRLGEEKL DSNVPIYTA SVEEVKCMVE EEGSFEILYL QTFKLRYDAG 300
 FSIDDDCQVR SHSPVYSDEH ARAAHVASLI RSVYEPILAS HFGEAIIPDI FHRFATNAAK 360
 VIRLGKGFYN NLIISLAKKP EKSDI 385
 45 <210> 4
 <211> 1360
 50 <212> Nucleic acid
 <213> Coffea arabica
 <400> 4
 55 GTCCTGCATA TGAATGGAGC TCCAAGAAGT CCTGCATATG AATGGAGGCG AAGGCGAAGC 60

EP 1 197 558 A2

AAGCTACGCC AAGAATTCAT CCTTCAATCA ACTGGTTCTC GCCAAGGTGA AACCTGTCCT 120
TGAACAATGC GTACGGGAAT TGTTCGCGGC CAACTTGCCC AACATCAACA AGTGCATTAA 180
AGTTGCAGAT TTGGGATGCG CTTCCGGACC AAACACACTT TTAACCGTTT GGGACACTGT 240
ACAAAGTATT GACAAAGTTA AGCAAGAAAT GAAGAATGAA TTAGAACGTC CCACCATTCA 300
GGTTTTTCTG ACTGATCITT TCCAAAATGA TTTCAATTCG GTTTTCATGC TGCTGCCAAG 360
CTTCTACCGC AAACCTTGAGA AAGAAAATGG ACGCAAAATA GGATCGTGCC TAATAGCCGC 420
AATGCCTGGC TCTTCCACG GCAGACTCTT CCCCAGGAG TCCATGCATT TTTTACACTC 480
TTCTTACAGT CTTTCACTTT TATCCCAGGT TCCCAGCGGT TTGGTGAAGT AATTGGGGAT 540
CACTGCGAAC AAAAGGASCA TTTACTCTTC CAAAGCAAGT CCTCCGCCCC TCCAGAAGGC 600
ATATTTGGAT CAATTTACGA AAGATTTTAC CACATTTTTA AGGATGCGTT CGGAAGAGTT 660
GCTTTCACGT GGCCGAATGC TCCTTACTTG CATTGTGAAA GGAGATGAAT GCGACGGCCC 720
GAATACCATG GACTTACTTG AGATGGCAAT AAACGACTTG GTTGCTGAGG GACGTCTGGG 780
GGAAGAAAAA TTGGACAGTT TCAATGTTCC AATCTATACA GCTTCAGTAG AAGAAGTAAA 840
GTGCATGGTT GAGGAGGAAG GTTCTTTTGA AATTTTATAC TTGCAGACTT TTAAGCTCCG 900
TTATGATGCT GGCTTCTCTA TTGATGATGA TTGCCAAGTA AGATCCCAT TCCCAGTATA 960
CAGCGATGAA CATGCTAGAG CAGCGCATGT GGCATCATT AATTAGATCAG TTTACGAACC 1020
CATCCTAGCA AGTCATTTTG GAGAAGCTAT TATACCTGAC ATATTCCACA GGTTCGCGAC 1080
GAATGCAGCA AAGGTTATCC GCTTGGGCAA AGGCTTCTAT AATAATCTTA TCATTTCTCT 1140
TGCCAAAAAA CCACAGAAGT CAGACATATA AAAGCTTGTT TTAGTTGGT TTTTCTGTTA 1200
TGGGTTGTTT TCTGATACGG GGAAGGATT CAGTGGCGTT GGGGTTCTAT CCGAGTATG 1260
TACTTTTTAT ATTATTAGTT GGTGTATAAT TATTATGTTA CATTGTTATA TTCGTAATA 1320
AAGTGACGTA CAAAATAAAA ATATTTTCAT AAAAAAAAAA 1360

<210> 5

<211> 385

<212> Amino acid

<213> Coffea arabica

<400> 5

MELQEVLMHN GEGDASYAK NSSFNQLVLA KVKPVLEQCV GELLRANLPN INKCIKVADL 60
GCASGPNTLL TVRDIQSID KVRQEMKNEL ERPTIQVFLT DLFQNDFNSV FMLLPSFYRK 120
LEKENGRIKIG SCLIAAMPGS FHGRFPPEES MHFLHSSYSL QFLSQVPSGL VTELGITANK 180
RSIYSSKASP PPVQKAYLDQ FTKDFTTFLR IRSEELLSRG RMLLTICKG DEFDPNTMD 240
LLEMAINDLV VEGHLEEEKL DSNVPIYAA SVEELKCIVE EEGSFEILYL ETFKLYDAG 300

FSIDDDCQVR SHSPEYSDEH ARAAHVASLL RSVYEPILAN HFGEAIIPDI FHRFATNAAK 360

VIRLGKGFYN NLIISLAKKP EKSDI 385

<210> 6

<211> 1304

<212> Nucleic acid

<213> Coffea arabica

<400> 6

TTTAGCAGTC CCAATTCGAT TTATGTACAA GTCCTGCATA TGAATGGAGC TCCAAGAAGT 60
 CCTGCATATG AATGGAGGCG AAGGCGATGC AAGCTACGCC AAGAATTCAT CCTTCAATCA 120
 ACTGGTTCTC GCCAAGGTGA AACCTGTCCT TGAACAATGC GTAGGGGAAT TGTTCGGGGC 180
 CAACTTGCCC AACATCAACA AGTGCATTAA AGTTGCGGAT TTGGGATGCG CTTCCGGACC 240
 AAACACACTT TTAACAGTTC GGGACATTGT ACAAAGTATT GACAAAGTTA GGCAAGAAAT 300
 GAAGAATGAA TTAGAACGTC CCACCATTCA GGTTTTTCTG ACTGATCTTT TCCAAAATGA 360
 TTTCAATTCTG GTTTTCATGT TGCTGCCAAG TTTCTACCGC AAACCTTGAGA AAGAAAATGG 420
 ACGCAAGATA GGATCGTGCC TAATAGCCGC AATGCCTGGC TCTTCCACG GCAGACTCTT 480
 CCCCAGAGGAG TCAATGCATT TTTTACACTC TTCTTACAGT CTTCATTTT TATCCCAGGT 540
 TCCCAGCGGT TTGGTGACTG AATTGGGGAT CACTGCGAAC AAAAGGAGCA TTTACTCTTC 600
 CAAAGCAAGT CCTCCGCCCG TCCAGAAGGC ATATTTGGAT CAATTTACGA AAGATTTTAC 660
 CACATTTTTA AGGATTCGTT CGGAAGAGTT GCTTTCACGC GGCCGAATGC TCCTTACTTG 720
 CATTTGCAAA GGACATGAAT TCGACGGCCC GAATACCATG GACTTACTTG AGATGGCAAT 780
 AAACGACTTG GTTGTGAGG GACATCTGGA GGAAGAAAAA TTGGACAGTT TCAATGTTCC 840
 AATCTATGCA GCTTCAGTAG AAGAATTAAA GTGCATAGTT GAGGAGGAAG GTTCTTTTGA 900
 AATTTTGTAC TTGGAGACTT TTAAGCTCCG TTATGATGCT GGCTTCTCTA TTGATGATGA 960
 TTGCCAAGTA AGATCCCATT CCCCAGAATA CAGCGATGAA CATGCTAGAG CAGCGCATGT 1020
 GGCATCATT CTTAGATCAG TTTACGAACC CATCCTCGCA AATCATTTTG GAGAAGCTAT 1080
 TATACCTGAC ATATTCCACA GGTTTGCGAC GAATGCAGCA AAGGTTATCC GCTTGGGCAA 1140
 AGGCTTCTAT AATAATCTTA TCATTTCTCT TGCCAAAAAA CCAGAGAAGT CAGACATATA 1200
 AAAGCTTGTT TATAGTTGGT TTTTGTGCTA TGGTTTGT TTCTGATACGG GGAAAGGATT 1260
 TAGTGCGGTT GGGGTTCAAA AAAAAAAAAA AAAAAAAAAA AAAA 1304

<210> 7

<211> 372

<212> Amino acid

<213> Coffea arabica

<400> 7

MELQEVLRMN GEGDTSYAK NSAYNQLVLA KVKPVLEQCV RELLRANLPN INKCIKVADL 60
 GCASGPNTLL TVRDIVQSID KVGQEKKNEL ERPTIQIFLN DLFPNDFNSV FKLLPSFYRK 120
 LEKENGRKIG SCLIGAMPGS FYSRLFPEES MHFLHSCYCL QWLSQVPSGL VTELGISTNK 180
 GSIYSSKASR LPVQKAYLDQ FTKDFTTFLR IHSEELFSHG RMLLTQICKG VELDARNAID 240
 LLEMAINDLV VEGHLEEEKL DSFNLPVYIP SAEVVKCIVE EEGSFEILYL ETFKVLVDAG 300
 FSIDDEHIKA EYVASSVRV YEPILASHFG EAIIPDIFER FAKHAAKVLP LGKGFYNNLI 360
 ISLAKKPEKS DV 372

<210> 8

<211> 1316

<212> Nucleic acid

<213> Coffea arabica

<400> 8

CTTTGCGAGT CCCAATTTGA TTTATGTACA AGTCCTGCAT ATGAATGGAG CTCCAAGAAG 60
 TCCTGCGGAT GAATGGAGGC GAAGGCGATA CAAGCTACGC CAAGAATTCA GCCTACAATC 120
 AACTGCTTCT CGCCAAGCTC AAACCTGTCC TTCAACAATG CGTACCGGAA TTGTTGCCGG 180
 CCAACTTGCC CAACATCAAC AAGTGCATTA AAGTTGCGGA TTTGGGATGC GCTTCTGGAC 240
 CAAACACACT TTAAACAGTT CGGGACATTG TCCAAAGTAT TGACAAAGTT GGCCAGGAAA 300
 AGAAGAATGA ATTAGAACGT CCCACCATTG AGATTTTCTT GAATGATCTT TTCCCAAATG 360
 ATTTCAATTC GGTTTTCAAG TTGCTGCCAA GCTTCTACCG CAACTTGAG AAAGAAAATG 420
 GACGCAAAAT ACGATCGTCC CTAATAGGGC CAATGCCCCG CTCTTTCTAC AGCAGACTCT 480
 TCCCCGAGGA GTCCATGCAT TTTTACACT CTTGTTACTG TCTTCAATGG TTATCTCAGG 540
 TTCCTAGCGG TTTGGTGACT GAATTGGGGA TCAGTACGAA CAAAGGGAGC ATTTACTCTT 600
 CCAAAGCAAG TCGTCTGCCC GTCCAGAAGG CATATTTGGA TCAATTTACG AAAGATTTTA 660
 CCACATTCTT AAGGATTCAT TCGGAAGAGT TGTTTTTACA TGGCCGAATG CTCCTTACTT 720
 GCATTTGTAA AGGAGTTGAA TTAGACGCCC GGAATGCCAT AGACTTACTT GAGATGGCAA 780
 TAAACGACTT GGTGTTGAG GGACATCTGG AGGAAGAAAA ATTGGATAGT TTCAATCTTC 840
 CAGTCTATAT ACCTTCAGCA GAAGAAGTAA AGTGCATAGT TGAGGAGGAA GGTCTTTTGG 900

AAATTTTATA CCTGGAGACT TTTAAGGTCC TTTACGATGC TGGCTTCTCT ATTGACGATG 960
 AACATATTAA AGCAGAGTAT GTTGCATCTT CCGTTAGAGC AGTTTACGAA CCCATCCTCG 1020
 CAAGTCATTT TGGAGAAGCT ATTATACCTG ACATATTCCA CAGGTTTGCG AAGCATGCAG 1080
 CAAAGGTTCT CCCCTTGGGC AAAGGCTTCT ATAATAATCT TATCATTTCT CTCGCCAAAA 1140
 AGCCAGAGAA GTCAGACGTG TAAAAGTTTG TTTTGTGTT GGGGAAAGGA ATAAGTGCCG 1200
 TTGGGGGTCT TTCGGGTATT GTGCTTTTTA TATTATATTG TTTTGTATCC GTAATAAAAAG 1260
 TGGTGTGTAA GAATAAGATA TTTGACATAT ATTATTTTCA AAAAAAAAAA AAAAAA 1316

Claims

1. A polypeptide consisting of an amino acid sequence of following (a) or(b):
 - (a) an amino acid sequence defined by amino acid numbers from 1 to 378 shown in SEQ ID NO: 1 in a Sequence List,
 - (b) an amino acid sequence in which a part of said amino acid sequence (a) is deleted or another amino acid sequence is added to said amino acid sequence (a) or a part of amino acid sequence (a) is substituted with another amino acid sequence, the amino acid sequence (b) having the activity to biosynthesize theobromine using 7-methylxanthine as the substrate.
2. A polypeptide consisting of an amino acid sequence exhibiting at least 90% of homology with an amino acid sequence defined by amino acid numbers from 1 to 378 shown in SEQ ID NO: 1 in a Sequence List.
3. A gene encoding the polypeptide according to Claims 1 or 2.
4. A gene consisting of a base sequence of following (c), (d) or (e):
 - (c) a base sequence defined by base numbers from 1 to 1298 shown in SEQ ID NO: 2 in a Sequence List,
 - (d) a base sequence in which a part of base sequence (c) is deleted or another base sequence is added to said base sequence (c) or a part of base sequence (c) is substituted with another base sequence, the base sequence (d) encoding a polypeptide having the activity to biosynthesize theobromine using 7-methylxanthine as the substrate.
 - (e) a base sequence that hybridizes with said base sequence (c) under stringent condition, the base sequence (e) encoding a polypeptide having the activity to biosynthesize theobromine using 7-methylxanthine as the substrate.
5. A gene consisting of a base sequence exhibiting at least 90% of homology with a base sequence defined by base numbers from 1 to 1298 shown in SEQ ID NO: 2 in a Sequence List.
6. A transformed plant wherein expression of the gene according to Claims 3 to 5 is decreased in the plant to inhibit biosynthesis of theobromine.
7. The transformed plant according to Claim 6, wherein antisense gene method is utilized to inhibit biosynthesis of theobromine.
8. The transformed plant according to Claim 6, wherein said plant is selected from the group consisting of *Coffea arabica*, *Coffea canephora*, *Coffea liberica* and *Coffea dewevrei*.
9. A seed obtained from the transformed plant according to Claims 6 or 8.

EP 1 197 558 A2

10. A transformed plant wherein gene according to Claims 3 to 5 is introduced in the plant to increase biosynthesis of theobromine.
- 5 11. The transformed plant according to Claim 10, wherein said plant is selected from the group consisting of *Coffea arabica*, *Coffea canephora*, *Coffea liberica* and *Coffea dewevrei*.
12. A seed obtained from the transformed plant according to Claims 10 or 11.
- 10 13. A method for production of a transformed plant in which biosynthesis of theobromine is inhibited in the plant by decreasing expression of the gene according to Claims 3 or 5.
14. The method according to Claim 13, wherein antisense gene method is utilized to inhibit biosynthesis of theobromine.
- 15 15. A method for production of a transformed plant in which biosynthesis of theobromine is enhanced in the plant by enhancing expression of the gene according to Claims 3 or 5.

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2

A

GTCTGCATA	TGAATGGAGC	TCCAAGAACT	CCTGCATATG	AATGGAGGCG	AAGGCGAAGC	AAGCTACGEC	AAGAATTCAT	CCTTEAATCA	90
ACTGGTCTC	CCCAAGGTGA	AACCTGTCT	TGAACAATGC	GTACGGGAAT	TGTTGGGGCG	CAACTTGCCC	AACATCAACA	AGTGCAATTA	180
AGTTGCAGAT	TGGGATGGCG	CTTCCGGACC	AAACACACTT	TTAACCGTIT	GGGACACTGT	ACAAAGTATT	GACAAAGTTA	AGCAAGAAAT	270
GAAGAATGAA	TTAGAACGTC	CCACCAATCA	GGTTTTCTG	ACTGATCTTT	TCCAATAATGA	TTTCAATTGG	GTTTTCATGC	TGCTGCCAAG	360
CTTCTACCGC	AAACTTGAGA	AAGAAAATGG	ACGCAAAATA	GGATCGTGCC	TAATAGCCGC	AATGCTCGGC	TCITTECAGC	GCAGACTCTT	450
CCCCGAGGAG	TCCATGGATT	TTTACACTCT	TTCTTACAGT	CTTCAGTITT	TATECCAGGT	TCCGACGGGT	TTGTTGACTG	AATTGGGGAT	540
CACATGCGAC	AAAAGGAGCA	TTTACTCTTC	CAAAAGCAAT	CTTCCGCGCG	TCCAGAGGCG	ATATTGGGAT	CAATTTCAGT	AAGATTTTAC	630
CACATTTTAA	AGGATGGGTT	CGGAAGAGTT	GCTTTACGTT	GGCCGAATGC	TCCTTACTTG	CATTTTGAT	GGAGATGAAT	GCAGCGGCC	720
GAATACCATG	GACTTACTTG	AGATGGCAAT	AAAGCACTTG	GTTCGTGAGG	GACGTCTGGG	GGAAAGAAAA	TTGGACAGTT	TCAATGTTCC	810
AATCTATACA	GCTTCAGTAG	AAGAATGAAA	GTGCATGTTT	GAGGAGGAAG	GTCTTTTGA	AATTTTATAC	TTGCAGACTT	TTAAGTCTCG	900
TTATGATGCT	GGCTCTCTTA	TTGATGATGA	TTGCCAAGTA	AGATCCCAAT	CCCCAGTATA	CAGCGATGAA	CATGCTAGAG	CAGCGCATGT	990
GGCATCTTAA	ATTAGATCAG	TTTACGAACC	CATCTAGCA	AGTCATTTTG	GAGAAGCTAT	TATACCTGAC	ATATTCCACA	GGTTTGGCAG	1080
GAATGCACGA	AAGGTTATCC	CGTTGGGCAA	AGGCTCTCTAT	AATAATCTTA	TCATTCTCT	TGCCAAAAAA	CCAGAGAAGT	CAGACATATA	1170
AAAGCTTGTT	TTTACTGGT	TTTGTCTCTA	TGGGTGTGTT	TCGTATACGG	GGAAAGGATT	CAGTGCGGTT	GGGTTCTAT	CCGAGTATTG	1260
TACTTTTAT	ATTATTAGTT	GGTGTATAT	TATTATGTTA	CATTGTATATA	TTGCTAATAA	AAGTGACGTA	CAAAAAATAA	ATATTTCAT	1350
AAAAAATAAA									1360

B

TTTACGAGTC	CCAATTGAT	TTATGTACAA	GTCTGCATA	TGAATGGAGC	TCCAAGAACT	CCTGCATATG	AATGGAGGCG	AAGGCGAAGC	90
AAGCTACGEC	AGAATTCAT	CTTCAATCA	ACTGGTCTC	CCCAAGGTGA	AACCTGTCT	TGAACAATGC	GTACGGGAAT	TGTTGGGGCG	180
CAACTTGCCC	AACATCAACA	AGTGCAATTA	AGTTGGGGAT	TGGGATGGCG	CTTCCGGACC	AAACACACTT	TTAACCGTIT	GGGACACTGT	270
ACAAAGTATT	GACAAAGTTA	GGCAAGAAAT	GAAGAATGAA	TAGAACGTC	CCACCAATCA	GGTTTTCTG	ACTGATCTTT	TCCAATAATGA	360
TTTCAATTGG	GTTTTCATGT	TGCTGCCAAG	TTTCTACCGC	AAACTTGAGA	AAGAAAATGG	ACGCAAAATA	GGATCGTGCC	TAATAGCCGC	450
AATGCTCGGC	TCITTECAGC	GCAGACTCTT	CCCCGAGGAG	TCAATGGATT	TTTACACTCT	TTCTTACAGT	CTTCAATTGG	TATCCAGGTT	540
TCCGACGGGT	TTGTTGACTG	AATTGGGGAT	CACATGCGAC	AAAAGGAGCA	TTTACTCTTC	CAAAAGCAAT	CTTCCGCGCG	TCCAGAGGCG	630
ATATTGGGAT	CAATTTCAGTA	AAGATTTTAC	CACATTTTAA	AGGATTCGTT	CGGAAGAGTT	GCTTTACGCG	GGCCGAATGC	TCCTTACTTG	720
CATTTCGAAA	GGAGATGAAT	TCCGAGGCC	GAATACCATG	GACTTACTTG	AGATGGCAAT	AAAGCACTTG	GTTCGTGAGG	GAATCTCGA	810
GGAAAGAAAA	TTGGACAGTT	TCAATGTTCC	AATCTATGCA	GCTTCAGTAG	AAGAATTAAT	GTGCATAGTT	GAGGAGGAAG	GTCTTTTGA	900
AATTTTGTAC	TTGGAGACTT	TTAAGTCTCC	TTATGATGCT	GGCTCTCTTA	TTGATGATGA	TTGCCAAGTA	AGATCCCAAT	CCCCAGTATA	990
CAGCGATGAA	CATGCTAGAG	CAGCGCATGT	GGCATCTTAA	CTTAGATCAG	TTTACGAACC	CATCTCTGCA	AATCAATTTG	GAGAAGCTAT	1080
TATACCTGAC	ATATTCCACA	GGTTTGGCAG	GAATGCACGA	AAGGTTATCC	CGTTGGGCAA	AGGCTCTCTAT	AATAATCTTA	TCATTCTCT	1170
TGCAAAATAA	CCAGAGAAGT	CAGACATATA	AAAGCTTGTT	TATAGTGGT	TTTTGTCTTA	TGTTTGTGTT	TCGTATACGG	GGAAAGGATT	1260
TAGTGGGTT	GGGTTCTAAA	AAAAAATAAA	AAAAAATAAA	AAAA					1304

C

CTTTGGCAGT	CCCAATTGGA	TTTATGTACA	AGTCTGCAT	ATGAATGGAG	CTCCAAGAAG	TCTTGGGAT	GAATGGAGGC	GAAGCGATA	90
CAAGCTACGC	CAAGAATICA	GCCTACAATC	AACCTGTCT	CCCAAGGTGA	AAACCTGTCC	TTGAACAATGC	GTACGGGAAT	TGTTGGGGCG	180
CCAACTTGCC	CAACATCAAC	AAGTGCAATTA	AAGTTGGGGA	TTTGGGATGC	GCTTCTGGAC	CAAAACACTT	TTTAACAGTT	GGGACACTTG	270
TCCAAGTATT	TGACAAAGTT	GGCCAGGAAA	AGAAGAATGA	ATTAGAACGT	CCCAACATTC	AGATTTTCT	GAATGATCTT	TCCCAAGT	360
ATTTCAATTC	GGTTTCAAG	TTGCTGCCAA	GCTTCTACCG	CAAACTTGAG	AAAAGAAAAT	GAAGCAAAAT	AGGATCGTGC	CTAATAGGGG	450
CAATGGCCGG	CTCTTCTAC	AGCAGACTCT	TCCCGAGGAG	GTCCATGAT	TTTTTACACT	CTTGTACTG	TCCTCAATGC	TTATCTCAGG	540
TTCTCTAGCG	TTTGGTACT	GAATTTGGGA	TCAGTACGAA	CAAAAGGAGC	ATTACTCTT	CCAAAGCAAG	TCGTCTGCC	GTCCAGAAAG	630
CATATTGGGA	TCAATTTAGC	AAAGATTTTA	CCCAATTTCT	AAGGATTGAT	TGCGAAGAGT	TGTTTTCA	TGCGCGAATG	CTCTTACTT	720
GCATTGTGAA	AGGAGTTGAA	TTAGAGCGCC	GGATGCGCAT	AGACTTACTT	CAGATGGCAA	TAAACGACTT	GGTTGTTGAG	GGACATCTCG	810
AGGAAGAAAA	ATTGGATAGT	TTCAATCTTC	CAGTCTATAT	ACCTTCAGCA	GAAGAAGTAA	AGTGCATAGT	TGAGGAGGAA	GGTTCTTTTG	900
AAATTTTATA	CTTGAGAGCT	TTTAAAGTCC	TTTACGATGC	TGGCTCTCT	ATTGACGATG	AACATATTA	AGCAGAGTAT	GTTCATCTT	990
CCGTACAGGC	AGTTTACGAA	CCCATCTCTG	CAAGTCATTT	TGGAGAACT	ATTATACCTG	ACATATTCCA	CAGGTTTGG	AAGCATGCAG	1080
CAAAAGTTCT	CCCTTGGCG	AAAGGCTCT	ATAAATATCT	TATCATTTCT	CTCGCAAAA	AGCCAGAGAA	GTCCAGACTG	TAAAGTTTG	1170
TTTTGTGTT	GGGGAAGGA	ATAAGTCCG	TTGGGGTCT	TTCCGATTT	GTGCTTTTGA	TATTATATG	TTTTGTATCC	GTAATAAAG	1260
TGTTGTGTA	GAATAAGATA	TTTGACATAT	ATTATTTTCA	AAAAAATAAA	AAAAA				1316

D

AGCAGTCCGA	ATTGATGTT	CTGCAATG	AATGGAGTCC	CAAGAAGTCC	TGCATATGAA	TGAAGGTGAA	GGCGATACAA	GCTACGCCAA	90
GAATGCATCC	TACAATCTGG	CTCTGCCAA	GGTGAACCT	TTCTTGAAC	AATGCATACG	AGAAATTTTG	CGGGCAACT	TGCCCAACAT	180
CAACAAGTCC	ATTAAAGTTG	CGGATTTGGG	ATGCGTCTCT	GGACCAAAAC	CACCTTTTAA	AGTGGGGAC	ATTGTGCAAA	GTATTGACAA	270
AGTTGGCAG	GAAGCAAGCA	ATGAATTAGA	ACGTCCCAAC	ATTGAGATTT	TCTGAATGA	TCITTTCCAA	AATGATTICA	ATTGCGTTTT	360
CAAGTTGCTG	CCAAAGTCT	ACCCGAAAT	CGAGAAAGAA	AATGGAGCGA	AGATAGGATC	GTGCTTAATA	AGCGCAATGC	CTGGCTCTT	450
TACGGCAGGA	CTCTTCCCC	AGGAGTCCAT	GCATTTTGT	CACCTTGTIT	ACAGTTTICA	TTGGTTATCT	CAGGTTCCCA	CGGTTTGGT	540
GATTTGAATTG	GGGATTTGGT	CAACAAGAGG	GAGTATTATC	TTTCCAAAG	GATGTCTCC	GGCGTCCAG	AAGGCATATT	TGATCAAAIT	630
TACGAAGAAT	TTTACCAAT	TTCTAAGGAT	TCATTGGAAA	GAGTGTITTT	CACGTGGCCG	AATGCTCTT	ACCTGCAATT	GTAAAGTAGA	720
TGAATTCGAC	GAACGGAATC	CCCTAGACTT	ACTTGACAT	GCAATAAAG	ACTTGATGT	TGAGGGGACTT	CTGGAGGAG	AAAAATTGGA	810
TAGTTTCAAT	ATTCATCTT	TTTACACTTC	AGCAGAAAG	GTAAAGTGA	TAGTTGAGGA	GGAAAGTTCT	TGCAAAATTT	TATATCTGGA	900
GACTTTTAA	AGCATTTATG	ATGCTGCTT	CTCATTTGAT	GATGATTAC	CAGTAAGATC	CCATGAACAA	ATTAAAGCAG	AGTATCTGGC	990
ATCATTAAT	AGATCAGTT	AGCAACCCAT	CCTGCAAGT	CATTTTGGAG	AGGCTATTAT	GCCTGACTTA	TTCCACAGGC	TTGGGAAGCA	1080
TGCAAGAAAG	GTCTCCGACA	TGGGCAAAAG	CTGCTATAT	AATCTTATCA	TTTCTCTCGC	CAAAAAGCCA	GAGAGTCA	ACGTGTAAAA	1170
GTGTTGTTTT	AGTGGTTTT	TGTCCGTTG	GGGTCCTTC	GGGTATTGTC	GTGTTGATT	GTAAATAAAA	GTGATGTGCA	AGAAATAGAT	1260
ATTAGTAGCA	ATATTTCAT	AAAAAATAAA	AAAAAATAAA						1298

FIG. 3

MXMT1	MELQEVLMNEGEGDTSYAKNASYN-LALAKVKPFLEQCTRELLRANLN	49
MTL1G::EA::S:F:Q:V::V::V::	50
MTL2G::A::S:F:Q:V::V::VG::	50
MTL3R::G::SA::Q:V::V::V::	50
MXMT1	INKCIKVADLCASGNILLTVRDIVQSTDKVQDEKNELERPTIQIFLN	99
MTL1W:T::K::M::V::T	100
MTL2R::M::V::T	100
MTL3K::	100
MXMT1	DLFQDFNSVFKLLPSFYRKLEKNGRKGCSCLISAMPGSFYGRLPPEE	149
MTL1M::A::H::	150
MTL2M::A::H::	150
MTL3	...P::S::	150
MXMT1	MHFLHSCYSVHLSQVPSGLVTELGIGANKGSTYSSKGRPPVQKAYLDQ	199
MTL1S::LQF::T::T::R::ASP::	200
MTL2S::LQF::T::T::R::ASP::	200
MTL3CLQ::T::ST::AS:L::	200
MXMT1	FTKDFTFIRHSKELFSRGMLLTCTCKVDESDENPLDLLDMAINLI	249
MTL1MR:E::L::G::C:G::TM::E::V	250
MTL2R:E::L::G::G::TM::E::V	250
MTL3E::H::GE:L:AR:AI::E::V	250
MXMT1	VEGLLEPKLDSFNIPFFTPSAEEVKCIVEERGSCETLYLEIFKAHYDAA	299
MTL1	A::R:G::V:IY:A:V::M::F::Q::LR::G	300
MTL2	:::H::V:IYAA:V::L::F::LR::G	300
MTL3	:::H::L:VYI::F::VL::G	300
MXMT1	FSIDDDYFVRSH-----EQIKAEYVASLRSVYEPTIASHFGEADMDL	343
MTL1CQ::SPVYSD:HAR:AH::I::I	350
MTL2CQ::SPEYSD:HAR:AR::L::N::I::I	350
MTL3EH-----SV:A::I::I	337
MXMT1	FHFLAKHAQVLMKGGCYNLIISLAKKPKESDV	378
MTL1	:::F:IN::IRL::F::I	365
MTL2	:::F:IN::IRL::F::I	365
MTL3	:::F::FL::F::	372

FIG. 4




FIG. 5






FIG. 6



THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 197 558 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
04.12.2002 Bulletin 2002/49

(51) Int Cl.7: **C12N 15/82, C12N 9/10,
C12N 15/11**

(43) Date of publication A2:
17.04.2002 Bulletin 2002/16

(21) Application number: **01122628.9**

(22) Date of filing: **27.09.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

- **Kusano, Tomonobu**
Nara City, Nara Pref. (JP)
- **Koizumi, Nozomu**
Ikoma City, Nara Pref. (JP)

(30) Priority: **06.10.2000 JP 2000307149**

(71) Applicant: **Nara Institute of Science and
Technology**
Ikoma City, Nara Pref. (JP)

(74) Representative:
**Wibbelmann, Jobst, Dr., Dipl.-Chem.
Wuesthoff & Wuesthoff,
Patent- und Rechtsanwälte,
Schweigerstrasse 2
81541 München (DE)**

(72) Inventors:
• **Sano, Hiroshi**
Ikoma City, Nara Pref. (JP)

(54) **Theobromine synthase polypeptide of coffee plant and the gene encoding said polypeptide**

(57) According to the present invention, the polypeptide of theobromine synthase derived from *Coffea arabica* and the gene encoding said polypeptide are provided. As theobromine synthase participates in bio-

synthesis of caffeine, caffeineless coffee would be obtained by preparing a transformed plant, wherein expression of gene encoding said enzyme is inhibited.

EP 1 197 558 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 01 12 2628 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	KATO M ET AL: "Caffeine synthase gene from tea leaves" NATURE, vol. 406, 31 August 2000 (2000-08-31), pages 956-957, XP002173208 ISSN: 0028-0836 * the whole document *	1-9,13, 14	C12N15/82 C12N9/10 C12N15/11
X	MAZZAFERA P. ET AL.: "S-ADENOSYL-L-METHIONINE: THEOBROMINE 1-N-METHYLTRANSFERASE, AN ENZYME CATALYSING THE SYNTHESIS OF CAFFEINE IN COFFEE" PHYTOCHEMISTRY, vol. 37, no. 6, - 1994 pages 1577-1584, XP001040595 * page 1577, column 2, paragraph 3; figure 1; table 1 *	1-9,13, 14	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
BERLIN		1 October 2002	Schönwasser, D
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>L : document cited in the application</p> <p>I : document cited for other reasons</p> <p>R : member of the same patent family, corresponding document</p>	

EP0 FORM 1603 21.8C (PG400)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number

EP 01 12 2628

Claim(s) searched completely:
1-5,7-12,14,15

Claim(s) searched incompletely:
6,13

Reason for the limitation of the search:

Present claims 6 and 13 relate to a transgenic plant or a method for producing such a plant defined by reference to a desirable characteristic or property, namely the desirable property of a transgenic plant to have a decreased gene expression.

The claims cover all transgenic plants and methods for producing such plants having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC for only a very limited number of such transgenic plants and methods for producing such plants. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the product and the method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the transgenic plants and methods for producing such plants as claimed in claims 7 and 14 and described on page 5, line 31 to page 6, line 22.

European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 12 2628

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	KATO MISAKO ET AL.: "Purification and characterization of caffeine synthase from tea leaves" PLANT PHYSIOLOGY, vol. 120, no. 2, June 1999 (1999-06), pages 579-586, XP002173207 ISSN: 0032-0889 * figure 5; table II *	1-5	
X	SUZUKI T. ET AL.: "Biosynthesis of Caffeine by Tea-Leaf Extracts" BIOCHEMICAL JOURNAL, vol. 146, 1975, pages 87-96, XP001040587 * page 89, column 2, paragraph 2 - page 91, column 2, paragraph 3 * * page 94, column 1, paragraph 2 *	1-5	
P,X	OGAWA M. ET AL.: "7-Methylxanthine Methyltransferase of Coffee Plants" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 11, 16 March 2001 (2001-03-16), pages 8213-8218, XP002215148 * the whole document *	1-15	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
P,X	EP 1 055 727 A (MITSUI CHEMICALS INC) 29 November 2000 (2000-11-29) SEQ ID NO:1 * page 2, paragraph 1; example 10 * * page 6, paragraph 2 * * page 6, paragraph 4 - paragraph 5 * * page 8, paragraph 2 - paragraph 4 *	1-15	
	-/--		



PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 12 2628

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,X	<p>ASHIHARA H. ET AL.: "Caffeine: a well known but little mentioned compound in plant science"</p> <p>TRENDS IN PLANT SCIENCE, vol. 6, no. 9, September 2001 (2001-09), pages 407-413, XP002215149</p> <p>* page 407, column 1, line 21 - line 27; table 1 *</p> <p>* page 411, column 2, paragraph 4 - page 413, column 1, paragraph 1 *</p> <p>-----</p>	1-15	
			<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 2628

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

01-10-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1055727 A	29-11-2000	EP 1055727 A2	29-11-2000
		JP 2001037490 A	13-02-2001

EP0 FORM PC/59

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)